Hussman Strategic Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Hussman Strategic Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61M	Sell	31,500 -21,000	-40%	-$1.68M	0.6%	62
2026 Q1	$4.04M	Buy	52,500 +21,000	+67%	+$1.64M	0.87%	6
2025 Q4	$2.49M	Buy	+31,500	New	+$2.73M	0.6%	51
2025 Q1	–	Sell	-31,500	Closed	-$1.74M	–	240
2024 Q4	$1.74M	Buy	+31,500	New	+$1.81M	0.51%	79
2024 Q3	–	Sell	-42,000	Closed	-$2.67M	–	226
2024 Q2	$2.67M	Buy	42,000 +10,500	+33%	+$682K	0.74%	43
2024 Q1	$2.18M	Buy	+31,500	New	+$1.9M	0.51%	76
2021 Q3	–	Sell	-30,400	Closed	-$1.07M	–	319
2021 Q2	$1.07M	Hold	30,400	–	–	0.22%	174
2021 Q1	$1.1M	Hold	30,400	–	–	0.23%	170
2020 Q4	$883K	Sell	30,400 -5,100	-14%	-$146K	0.23%	165
2020 Q3	$1M	Hold	35,500	–	–	0.26%	153
2020 Q2	$1.15M	Hold	35,500	–	–	0.29%	134
2020 Q1	$1.45M	Hold	35,500	–	–	0.39%	99
2019 Q4	$2.19M	Hold	35,500	–	–	0.7%	46
2019 Q3	$2.59M	Buy	35,500 +10,500	+42%	+$786K	0.73%	46
2019 Q2	$2.06M	Buy	25,000 +11,500	+85%	+$818K	0.57%	73
2019 Q1	$952K	Sell	13,500 -3,500	-21%	-$206K	0.23%	156
2018 Q4	$765K	Hold	17,000	–	–	0.18%	173
2018 Q3	$961K	Buy	+17,000	New	+$1.04M	0.28%	126

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's ANIP Position: Q2 2026 in Review

Hussman Strategic Advisors reduced its ANI Pharmaceuticals (ANIP) stake by 40% in Q2 2026, selling an estimated $1.68M and leaving 31,500 shares worth $2.61M. The position accounts for 0.6% of the portfolio, ranked #62.

Hussman Strategic Advisors first reported a position in ANIP in Q3 2018 and has held it in 18 quarters since. The position peaked at $4.04M in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Hussman Strategic Advisors held 31,500 shares of ANI Pharmaceuticals worth $2.61M as of Q2 2026.
Hussman Strategic Advisors sold 21,000 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.68M.
ANI Pharmaceuticals made up 0.6% of Hussman Strategic Advisors's portfolio in Q2 2026, its #62 holding.
Hussman Strategic Advisors first reported a position in ANI Pharmaceuticals in Q3 2018 and has held it in 18 quarters since.
Hussman Strategic Advisors's ANI Pharmaceuticals position peaked at $4.04M in Q1 2026.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.